--- title: "Cellectar Biosciences (CLRB) stock and investor profile" url: "https://aibio.space/companies/cellectar-biosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "Cellectar Biosciences, Inc. (NASDAQ: CLRB), United States. The directory classifies it as Pharmaceuticals: Major." --- CLRB Cellectar Biosciences, Inc. NASDAQ · United States # Cellectar Biosciences (CLRB) news Financings · 2025-10-10 ## [Cellectar Biosciences gets about $5.8 million gross from warrant inducement, issues new warrants](https://aibio.space/news/cellectar-biosciences-gets-about-5-8-million-gross-warrant-inducement/) Holders exercised existing warrants at $5.25 per share and paid $0.125 per new warrant. Cellectar anticipates its cash and the net proceeds will fund operations into the third quarter of 2026. ## Latest Cellectar Biosciences news 1. 2025-10-10 Financings [Cellectar Biosciences raises about $5.8 million from warrant inducement deal](https://aibio.space/news/cellectar-biosciences-raises-about-5-8-million-warrant-inducement-deal/) Holders exercised warrants for 1,048,094 shares at $5.25 and received new warrants at $6.00. Cellectar says cash should last into the third quarter of 2026. 2. 2025-06-05 Financings [Cellectar Biosciences agrees to warrant inducement deal for about $2.5 million gross proceeds](https://aibio.space/news/cellectar-biosciences-agrees-warrant-inducement-deal-about-2-5-million/) Holders of warrants for 8,301,322 shares agreed to exercise at a reduced price of $0.3041 per share. Ladenburg Thalmann & Co. Inc. is placement agent, and closing is expected on or about June 6, 2025. 3. 2024-11-13 Distress [Cellectar Biosciences delays quarterly report after restating past results](https://aibio.space/news/cellectar-biosciences-delays-quarterly-report-after-restating-past/) The company found that certain warrants and preferred stock issued before 2023 had not been accounted for properly. It estimated cash of $34.3 million at September 30, 2024. ## Cellectar Biosciences at a glance - **Ticker**: CLRB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $34.0 million ### Related companies - [Alpha Teknova](https://aibio.space/companies/alpha-teknova/) NASDAQ: TKNO - [Evommune](https://aibio.space/companies/evommune/) NYSE: EVMN - [Aclaris Therapeutics](https://aibio.space/companies/aclaris-therapeutics/) NASDAQ: ACRS - [Achieve Life Sciences](https://aibio.space/companies/achieve-life-sciences/) NASDAQ: ACHV - [Innovation Pharmaceuticals](https://aibio.space/companies/innovation-pharmaceuticals/) OTC: IPIX - [Rhythm Pharmaceuticals](https://aibio.space/companies/rhythm-pharmaceuticals/) NASDAQ: RYTM - [Amphastar Pharmaceuticals](https://aibio.space/companies/amphastar-pharmaceuticals/) NASDAQ: AMPH - [Avenue Therapeutics](https://aibio.space/companies/avenue-therapeutics/) OTC: ATXI ### Also on NASDAQ - [Decoy Therapeutics](https://aibio.space/companies/decoy-therapeutics/) DCOY - [Kyntra Bio](https://aibio.space/companies/kyntra-bio/) KYNB - [Actuate Therapeutics](https://aibio.space/companies/actuate-therapeutics/) ACTU - [ACADIA Pharmaceuticals](https://aibio.space/companies/acadia-pharmaceuticals/) ACAD - [Rezolute](https://aibio.space/companies/rezolute/) RZLT - [MDxHealth SA](https://aibio.space/companies/mdxhealth/) MDXH ## Cellectar Biosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$11.5 million](https://www.sec.gov/Archives/edgar/data/1279704/000110465926023167/) | [$26.1 million](https://www.sec.gov/Archives/edgar/data/1279704/000110465926023167/) | | Net income (loss) | [-$21.8 million](https://www.sec.gov/Archives/edgar/data/1279704/000110465926023167/) | [-$44.6 million](https://www.sec.gov/Archives/edgar/data/1279704/000110465926023167/) | | Cash from operations | [-$23.1 million](https://www.sec.gov/Archives/edgar/data/1279704/000110465926023167/) | [-$47.6 million](https://www.sec.gov/Archives/edgar/data/1279704/000110465926023167/) | | Cash and equivalents | [$13.2 million](https://www.sec.gov/Archives/edgar/data/1279704/000110465926095426/) | [$23.3 million](https://www.sec.gov/Archives/edgar/data/1279704/000110465926023167/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $34.0 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cellectar Biosciences What is the ticker symbol of Cellectar Biosciences? Cellectar Biosciences, Inc. trades under the ticker CLRB on NASDAQ. Where is Cellectar Biosciences listed? Cellectar Biosciences, Inc. is listed on NASDAQ. What is the SEC CIK of Cellectar Biosciences? The SEC Central Index Key (CIK) for Cellectar Biosciences, Inc. is 1279704. Its filings are on SEC EDGAR. How many shares does Cellectar Biosciences have outstanding? 9,452,108 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-13. Which country or territory is Cellectar Biosciences listed under? Our directory records Cellectar Biosciences, Inc. under United States. What does Cellectar Biosciences do? Our directory classifies Cellectar Biosciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Cellectar Biosciences? The ISIN recorded for Cellectar Biosciences, Inc. is US15117F8804. Does aibio.space cover Cellectar Biosciences? aibio.space lists Cellectar Biosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cellectar Biosciences incorporated? SEC records list its state or country of incorporation as DE. Is Cellectar Biosciences profitable? Cellectar Biosciences, Inc. reported a net loss of $21.8 million for the fiscal year ended Dec 31, 2025, and used $23.1 million of cash in operations, per its annual report to the SEC. How much does Cellectar Biosciences spend on research and development? $11.5 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Cellectar Biosciences have? $34.0 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Cellectar Biosciences (CLRB) stock news? Our latest story on Cellectar Biosciences, dated Oct 10, 2025: "Cellectar Biosciences gets about $5.8 million gross from warrant inducement, issues new warrants". Holders exercised existing warrants at $5.25 per share and paid $0.125 per new warrant. Cellectar anticipates its cash and the net proceeds will fund operations into the third quarter of 2026. [Source](https://aibio.space/news/cellectar-biosciences-gets-about-5-8-million-gross-warrant-inducement/). What is Cellectar Biosciences's latest stock offering or financing news? Our latest financing story, dated Oct 10, 2025: "Cellectar Biosciences gets about $5.8 million gross from warrant inducement, issues new warrants". Holders exercised existing warrants at $5.25 per share and paid $0.125 per new warrant. Cellectar anticipates its cash and the net proceeds will fund operations into the third quarter of 2026. [Source](https://aibio.space/news/cellectar-biosciences-gets-about-5-8-million-gross-warrant-inducement/). Who were the underwriters or placement agents on Cellectar Biosciences's offering? From our story: Ladenburg Thalmann & Co. Inc. is placement agent, and closing is expected on or about June 6, 2025. [Source](https://aibio.space/news/cellectar-biosciences-gets-about-5-8-million-gross-warrant-inducement/). ## Investor discussion: Cellectar Biosciences Members talk about Cellectar Biosciences (CLRB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cellectar Biosciences, newest first. Each line links the filing it comes from. 1. 2026-03-04 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465926023167/clrb-20251231x10k.htm) 2. 2025-10-10 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,3.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465925098725/tm2528473d1_8k.htm) 3. 2025-06-26 Financings Filed a final prospectus for a securities offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465925062834/tm2516057d3_s1.htm) 4. 2025-06-25 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465925062639/tm2519011d1_8k.htm) 5. 2025-06-18 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465925060661/tm2518341d1_ex99-1.htm) 6. 2025-06-13 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465925059400/tm2517987d1_8k.htm) 7. 2025-05-01 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465925042870/tm2513754d1_ex99-1.htm) 8. 2025-04-28 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465925040241/tm2512660-4_def14a.htm) 9. 2025-04-18 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465925036362/tm2512660-1_pre14a.htm) 10. 2025-03-13 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1279704/000141057825000329/clrb-20241231x10k.htm) 11. 2025-01-31 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465925008127/tm255128d1_8k.htm) 12. 2025-01-29 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1279704/000141057825000060/clrb-20240930xs1.htm) 13. 2024-12-11 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465924127487/tm2430732d1_ex99-1.htm) 14. 2024-11-13 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465924117781/tm2427113d2_nt10q.htm) 15. 2024-11-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1279704/000110465924113549/tm2427349d1_ex99-1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CLRB on TradingView](https://www.tradingview.com/symbols/NASDAQ-CLRB/). ## SEC filings and registration - **SEC name**: Cellectar Biosciences, Inc. - **CIK**: 1279704 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: CLRB (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932 - **Phone**: (608) 441-8120 - **Shares outstanding**: 9,452,108 as of 2026-08-11 (10-Q filed 2026-08-13) - **Former names**: NOVELOS THERAPEUTICS, INC.; COMMON HORIZONS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1279704/000110465926095460/tm2623056d1_8k.htm) filed 2026-08-13 - [10-Q](https://www.sec.gov/Archives/edgar/data/1279704/000110465926095426/clrb-20260630x10q.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/1279704/000110465926082719/tm2620219d1_8k.htm) filed 2026-07-10 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1279704/000110465926067626/tm261621d4_def14a.htm) filed 2026-05-28 - [S-1](https://www.sec.gov/Archives/edgar/data/1279704/000110465926063918/tm2614975d1_s1.htm) filed 2026-05-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1279704/000110465926063202/tm2614924d1_8k.htm) filed 2026-05-18 - [8-K](https://www.sec.gov/Archives/edgar/data/1279704/000110465926060693/tm2614602d1_8k.htm) filed 2026-05-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1279704/000110465926060678/clrb-20260331x10q.htm) filed 2026-05-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001279704), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cellectar Biosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CLRB, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cellectar Biosciences, Inc. - **Ticker**: CLRB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US15117F8804 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CLRB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cellectar-biosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cellectar Biosciences (CLRB) stock and investor profile", 2026-10-31, https://aibio.space/companies/cellectar-biosciences/